Growth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain

BMC Endocrine Disorders

Table 3 IGFBP3SDS during GH treatment according to randomization group

ITT	All		33 × 1		67 × 1		33 × 2		67 × 1 + 33 × 2
IGFBP3_SDS	n	Mean ± SD	n	Mean ± SD	n	Mean ± SD	n	Mean ± SD	Mean ± SD
At GH start	71	−0.3 ± 0.76	32	−0.4 ± 0.8	20	−0.2 ± 0.66	19	−0.3 ± 0.83	−0.3 ± 0.74
1^st year after GH start	76	0.3 ± 0.82	28	0.3 ± 0.73	24	0.4 ± 0.87	24	0.1 ± 0.87	0.2 ± 0.87
ΔIGFBP3_SDS 1^st year after GH start	63	0.6 ± 0.55	25	0.7 ± 0.47	19	0.7 ± 0.57	19	0.5 ± 0.64	0.6 ± 0.6
Prepubertal level	100	0.3 ± 0.54	37	0.3 ± 0.54	30	0.3 ± 0.63	33	0.3 ± 0.63	0.3 ± 0.54
Last pre-pubertal	90	0.4 ± 0.55	35	0.5 ± 0.49	28	0.4 ± 0.48	27	0.4 ± 0.68	0.4 ± 0.58
Study start	104	0.4 ± 0.63	38	0.4 ± 0.58	30	0.3 ± 0.63	36	0.4 ± 0.67	0.3 ± 0.65
1^st year after study start	100	0.3 ± 0.56	36	0.3 ± 0.43	30	0.3 ± 0.58	34	0.4 ± 0.67	0.4 ± 0.63
ΔIGFBP3_SDS1^st year after study start	100	0 ± 0.45	36	−0.1 ± 0.49	30	0 ± 0.51	34	0 ± 0.36	0 ± 0.43
Pubertal level	104	0.3 ± 0.56	38	0.2 ± 0.45	30	0.3 ± 0.62	36	0.3 ± 0.63	0.3 ± 0.62
ΔIGFBP3_SDS Pubertal level from study start	104	−0.1 ± 0.43	38	−0.2 ± 0.45^**	30	0.0 ± 0.51	36	−0.1 ± 0.32	−01 ± 0.42^*
Before study stop	104	0.2 ± 0.77	38	0.2 ± 0.82	30	0.3 ± 0075	36	0.1 ± 0.75	0.2 ± 0.75
After study stop	64	0.4 ± 0.8	23	0.6 ± 0.57	17	0.3 ± 0ö65	24	0.2 ± 1.01	0.2 ± 0.87

ISSN: 1472-6823